# Pharmacokinetics of Nivolumab and Erythropoietin in a Rat Model of Diet-Induced Obesity

## TL;DR

This study examines how obesity affects the drug levels of nivolumab and erythropoietin in rats, finding no significant differences in pharmacokinetics between lean and obese animals.

## Contribution

The study provides new insights into the pharmacokinetics of biologics in obese rats, showing no significant impact of obesity on drug exposure.

## Key findings

- No significant differences in pharmacokinetics of nivolumab and rHuEPO between lean and obese rats.
- Subcutaneous bioavailability of nivolumab was inversely related to the dose level.
- mg/kg dosing was necessary to achieve equivalent serum exposure in both lean and obese rats.

## Abstract

To investigate how obesity affects the pharmacokinetics of biologics in a rat model.

Male Long-Evans rats were fed a high-fat diet from the age of 3 weeks and development of obesity was monitored by measuring body size and composition (fat and lean mass). The animals received nivolumab (1 and 8 mg/kg) or recombinant human erythropoietin (rHuEPO, 1000 IU/kg) by intravenous or subcutaneous injection. Serum samples were collected and analyzed using an enzyme-linked immunosorbent assay (ELISA). Endogenous rat IgG was also measured in the nivolumab study. A standard noncompartmental analysis was performed to calculate pharmacokinetic parameters.

When dosed at mg/kg of total body weight approach, no significant differences in pharmacokinetics of nivolumab and rHuEPO between lean and obese cohorts were observed despite significant differences in the body composition. Subcutaneous bioavailability of nivolumab was inversely dependent on the dose level.

Pharmacokinetic parameters of two biologics tested in this work were not affected by obesity, and mg/kg dosing approach was necessary to achieve equivalent exposure in serum. The results were different from our previous findings of significant effect of obesity on pharmacokinetics of human IgG in rats. Additional studies with other biologics are urgently needed in preclinical and clinical settings.